NASDAQ: CMMBChemomab Therapeutics Ltd Stock
$0.49+0.01 (+2.08%)
Updated Dec 8, 2023
CMMB Price
$0.49
Fair Value Price
$0.58
Market Cap
$6.08M
52 Week Low
$0.43
52 Week High
$5.35
P/E
-0.19x
P/B
0.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.3
Operating Cash Flow
-$26M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CMMB Overview
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CMMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CMMB ($0.49) is undervalued by 16.09% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CMMB ($0.49) is not significantly undervalued (16.09%) relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CMMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CMMB due diligence checks available for Premium users.
Be the first to know about important CMMB news, forecast changes, insider trades & much more!
CMMB News
Valuation
CMMB fair value
Fair Value of CMMB stock based on Discounted Cash Flow (DCF)
Price
$0.49
Fair Value
$0.58
Undervalued by
16.09%
CMMB ($0.49) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CMMB ($0.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CMMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CMMB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
11.7x
Market
31.32x
CMMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
5.42x
CMMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CMMB's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.1M
Profit Margin
0%
CMMB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$23.4M
Liabilities
$5.4M
Debt to equity
0.3
CMMB's short-term assets ($22.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CMMB's short-term assets ($22.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CMMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.2M
Investing
$4.0M
Financing
$3.0k
CMMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CMMB vs Biotech Stocks
Chemomab Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.